• Explore /
  • Poster
  • / Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.

Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.

Abstract Video & Slides Poster

Authors

null

Emily C. Liang

Fred Hutchinson Cancer Center, Seattle, WA

Emily C. Liang , Alexandre V. Hirayama , Erik Lesley Kimble , Andrew Jay Portuguese , Aya Albittar , Aude Chapuis , Mazyar Shadman , Brian G. Till , Ryan Daniel Cassaday , Filippo Milano , Cameron John Turtle , David G. Maloney , Jordan Gauthier

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT01865617

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7511)

DOI

10.1200/JCO.2023.41.16_suppl.7511

Abstract #

7511

Poster Bd #

62

Abstract Disclosures

Similar Posters

First Author: Zhi Yang

First Author: Juan Martin-Liberal

First Author: Lei Xiao

Poster

2023 ASCO Annual Meeting

<span>Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.</span>

Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.

First Author: Shiqi Li